1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). This funding opportunity invites new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN).
The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Education organizations (independent school districts, public and state institutions of higher education, private institutions of higher education), Nonprofits (non-higher education with 501(c)(3), other Native American tribal organizations), and Government entities (county governments, state governments, federally recognized Native American tribal governments, public and Indian housing authorities, city or township governments). Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) is funded by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). This grant supports exploratory and developmental research projects in areas relevant to the NIH mission, specifically those that do not involve clinical trials. NCATS participates in this program to foster research that accelerates translational science.
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). This program supports small research projects that can be carried out in a short period of time with limited resources. NCATS participates in this program to support innovative pilot projects and feasibility studies in translational science.
Rare Diseases Clinical Research Network (RDCRN) is sponsored by National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS). The RDCRN is a program designed to advance medical research on rare diseases. It supports collaborative research among scientists and patient advocacy groups to study the natural history of rare diseases, develop new diagnostics and therapies, and conduct clinical trials.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article